NASDAQ:ATRA Atara Biotherapeutics (ATRA) Stock Price, News & Analysis $6.77 +0.27 (+4.15%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Atara Biotherapeutics Stock (NASDAQ:ATRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Atara Biotherapeutics alerts:Sign Up Key Stats Today's Range$6.47▼$6.9250-Day Range$6.40▼$10.1152-Week Range$3.92▼$19.15Volume15,314 shsAverage Volume25,609 shsMarket Capitalization$68.99 millionP/E RatioN/ADividend YieldN/APrice Target$9.50Consensus RatingModerate Buy Company Overview Atara Biotherapeutics is a biotechnology company focused on developing allogeneic T-cell immunotherapies for cancer and other serious diseases. Founded in 2012 and based in Thousand Oaks, California, the company’s approach uses immune cells from donors rather than cells collected from each individual patient. Its lead therapy, tabelecleucel, is an Epstein-Barr virus (EBV)-specific T-cell treatment for EBV-positive post-transplant lymphoproliferative disease, a rare complication that can occur after an organ or stem-cell transplant. The therapy is marketed in Europe under the name Ebvallo through a partnership with Pierre Fabre; it received conditional marketing authorization from the European Commission in 2022. Atara has also worked on other engineered and virus-specific T-cell therapies for oncology and autoimmune indications. Its research and commercial activities have included collaborations with pharmaceutical partners, while its pipeline and programs may change as development priorities evolve.AI Generated. May Contain Errors. Read More Atara Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreATRA MarketRank™: 3.09649478955 of 5 starsAtara Biotherapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 659th out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingAtara Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialAtara Biotherapeutics has a consensus price target of $9.50, representing about 40.3% upside from its current price of $6.77.Amount of Analyst CoverageAtara Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Atara Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Atara Biotherapeutics are expected to grow in the coming year, from ($0.22) to $1.38 per share. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.03% of the float of Atara Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverAtara Biotherapeutics has a short interest ratio ("days to cover") of 13.43, which indicates bearish sentiment.Change versus previous monthShort interest in Atara Biotherapeutics has recently decreased by 15.31%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtara Biotherapeutics does not currently pay a dividend.Dividend GrowthAtara Biotherapeutics does not have a long track record of dividend growth. News and Social Media1.4 / 5News Sentiment0.19 News SentimentAtara Biotherapeutics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Atara Biotherapeutics this week, compared to 5 articles on an average week. Company Ownership4.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $960,627.00 in company stock, which represents 1.3925% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Atara Biotherapeutics insiders have bought 2,440.18% more of their company's stock than they have sold. Specifically, they have bought $999,994.00 in company stock and sold $39,367.00 in company stock.Percentage Held by Insiders41.20% of the stock of Atara Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Atara Biotherapeutics' insider trading history. Receive ATRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATRA Stock News HeadlinesAtara Biotherapeutics (NASDAQ:ATRA) Share Price Crosses Below 200-Day Moving Average - Time to Sell?November 15 at 10:42 AM | americanbankingnews.comNasdaq Listing Risk Puts Atara Biotherapeutics’ Liquidity, Valuation and Capital Access in JeopardyNovember 12, 2026 | tipranks.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 18 at 1:00 AM | Behind the Markets (Ad)Atara Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 11, 2026 | marketscreener.comMAtara Biotherapeutics (ATRA) Expected to Release Quarterly Earnings on WednesdayNovember 10, 2026 | americanbankingnews.comAtara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug AdministrationOctober 14, 2026 | marketscreener.comMAtara Resubmits Tabelecleucel BLA To FDASeptember 30, 2026 | rttnews.comAtara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug AdministrationSeptember 30, 2026 | businesswire.comSee More Headlines ATRA Stock Analysis - Frequently Asked Questions How have ATRA shares performed this year? Atara Biotherapeutics' stock was trading at $18.09 at the beginning of 2026. Since then, ATRA stock has decreased by 62.6% and is now trading at $6.77. How were Atara Biotherapeutics' earnings last quarter? Atara Biotherapeutics, Inc. (NASDAQ:ATRA) released its quarterly earnings results on Tuesday, November, 10th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.02. The biotechnology company earned $1.22 million during the quarter, compared to analyst estimates of $800 thousand. When did Atara Biotherapeutics' stock split? Shares of Atara Biotherapeutics reverse split on the morning of Thursday, June 20th 2024.The 1-25 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Atara Biotherapeutics IPO? Atara Biotherapeutics (ATRA) raised $75 million in an IPO on Thursday, October 16th 2014. The company issued 5,000,000 shares at $14.00-$16.00 per share. Who are Atara Biotherapeutics' major shareholders? Top institutional shareholders of Atara Biotherapeutics include State Street Corp (0.26%) and Empowered Funds LLC (0.14%). Insiders that own company stock include Innovation Ltd Panacea, Brian N Cherry, Anhco Nguyen, Pascal Touchon, Eric J Hyllengren, Yanina Grant-Huerta and Jill Henrich. View institutional ownership trends. How do I buy shares of Atara Biotherapeutics? Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atara Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atara Biotherapeutics investors own include Allogene Therapeutics (ALLO), CRISPR Therapeutics (CRSP), Micron Technology (MU), AT&T (T), NVIDIA (NVDA), Tesla (TSLA) and Alibaba Group (BABA). Company Calendar Last Earnings11/10/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, ATRA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ATRA CIK1604464 Webwww.atarabio.com Phone(805) 623-4211FaxN/AEmployees10Year Founded2012Price Target and Rating Average Price Target for Atara Biotherapeutics$9.50 High Price Target$13.00 Low Price Target$6.00 Potential Upside/Downside+40.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.01) Trailing P/E RatioN/A Forward P/E Ratio4.91 P/E GrowthN/ANet Income$32.69 million Net Margins-368.58% Pretax Margin-368.55% Return on EquityN/A Return on Assets-73.19% Debt Debt-to-Equity RatioN/A Current Ratio1.72 Quick Ratio1.72 Sales & Book Value Annual Sales$120.77 million Price / Sales0.57 Cash Flow$5.13 per share Price / Cash Flow1.32 Book Value($3.72) per share Price / Book-1.82Miscellaneous Outstanding Shares10,190,000Free Float5,991,000Market Cap$68.99 million OptionableNo Data Beta0.28 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ATRA) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.